Seres Therapeutics
215 First Street
Cambridge
Massachusetts
02142
United States
Tel: 617-945-9626
Website: http://serestherapeutics.com/
Email: info@sereshealth.com
268 articles about Seres Therapeutics
-
Seres Therapeutics, Inc. announced that the company’s Phase III Ecospor IV study demonstrated a strong safety profile in addition to statistically significant positive results against C. difficile infection.
-
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
6/7/2022
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection.
-
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
6/1/2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of preclinical data supporting further investigation of a rationally designed microbial consortium candidate (DE486) to prevent or treat gastrointestinal (GI) mucositis.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Flagship Pioneering introduced ProFound Therapeutics, a new company that leverages previously undiscovered human proteins to develop treatments for many diseases.
-
Two experimental drugs from Seres Therapeutics and Vera Therapeutics celebrate clinical trial wins in hard-to-treat disease areas.
-
Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
5/22/2022
Seres Therapeutics, Inc. announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections by rapidly establishing a long-lasting colony of beneficial gut microbes, which can produce fatty acids that disrupt the C. difficile lifecycle.
-
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
5/10/2022
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting.
-
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
5/4/2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates.
-
Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022
4/28/2022
Seres Therapeutics, Inc. a leading microbiome therapeutics company, announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m. ET to discuss first quarter 2022 results and provide a general business update.
-
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
3/18/2022
Seres Therapeutics, Inc. will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting.
-
Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
3/10/2022
Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference.
-
Seres Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
3/3/2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET.
-
Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
3/1/2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2021 financial results and provided business updates.
-
Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022
2/22/2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 1, 2022 at 8:30 a.m. ET to discuss fourth quarter and full year 2021 results and provide a general business update.
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer
2/8/2022
Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that Paula Cloghessy, SPHR, SHRM-SCP, has joined Seres as Executive Vice President, Chief People Officer effective February 7, 2022, reporting directly to Eric Shaff, President and Chief Executive Officer.
-
Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022
1/24/2022
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host a webcast investor event on Monday, January 31, 2022, from 8:30 a.m. to 10:00 a.m. ET.
-
New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection
1/19/2022
Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced the publication in the New England Journal of Medicine of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile infection.
-
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference.